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Abstract
Background: High concentrations of recombinant activated factor VII (rFVIIa) can stop bleeding in hemophilic 
patients. However the rFVIIa dose needed for stopping haemhorrage in off-label indications is unknown. Since 
thrombin is the main hemostatic agent, this study investigated the effect of rFVIIa and tissue factor (TF) on thrombin 
generation (TG) in vitro.
Methods: Lag time (LT), time to peak (TTP), peak TG (PTG), and area under the curve after 35 min (AUCo-35 min) with 
the calibrated automated thrombography was used to evaluate TG. TG was assayed in platelet-rich plasma (PRP) 
samples from 29 healthy volunteers under basal conditions and after platelet stimulation with 5.0 μg/ml, 2.6 μg/ml, 0.5 
μg/ml, 0.25 μg/ml, and 0.125 μg/ml rFVIIa alone and in normal platelet-poor plasma (PPP) samples from 22 healthy 
volunteers, rFVIIa in combination with various concentrations of TF (5.0, 2.5, 1.25 and 0.5 pM).
Results: 
In PRP activated by rFVIIa, there was a statistically significant increase in TG compared to basal values. A significant TF
dose-dependent shortening of LT and increased PTG and AUCoT35 min were obtained in PPP. The addition of rFVIIa
increased the effect of TF in shorting the LT and increasing the AUCoT35 min w i t h  n o  e f f e c t  o n  P T G  b u t  w e r e
independent of rFVIIa concentration.
Conclusion: 
Low concentrations of rFVIIa were sufficient to form enough thrombin in normal PRP or in PPP when combined with 
TF, and suggest low concentrations for normalizing hemostasis in off-label indications.
Introduction
In severe bleeding it is vital to achieve normal hemosta-
sis. Replacement therapy with active plasma derivatives
can help to stop hemorrhaging, but treatment with
plasma or plasma-derived concentrates also carries the
risk of blood-borne virus transmission and volume over-
load. In recent years, treatments with recombinant acti-
vated factor VII (rFVIIa) has been proposed for
hemophilic patients with inhibitors, and in off-label use
for different bleeding conditions [1,2]. The optimal dose
of rFVIIa in off-label indications needed to manage
patients with severe uncontrolled bleeding is unknown,
and there is an estimated 1.4% incidence of thromboem-
bolism in patients treated with rFVIIa for conditions
other than hemophilia [3]. Low-dose rFVIIa produced
satisfactory results in cardiac patients with intractable
bleeding [4] and in trauma patients with coagulopathy
[5]. In this context, notwithstanding the presence of
underlying medical conditions, hemostasis could be
related to the concentrations of rFVIIa in the blood after
its infusion. However, high concentrations of rFVIIa
combined with tissue factor (TF) released after atheroma
inflammation, injury, or rupture could increase the
thrombin forming capacity in situ. In this situation, the
question is whether this constitutes a potential pro-
thrombogenic condition.
* Correspondence: draltman@arnet.com.ar
1 Centro de Trombosis de Buenos Aires, Viamonte 2008, 1056 Buenos Aires, 
Argentina
Full list of author information is available at the end of the articleAltman et al. Thrombosis Journal 2010, 8:8
http://www.thrombosisjournal.com/content/8/1/8
Page 2 of 7
In this study, the thrombin generation (TG) capacity of
different concentrations of rFVIIa was assayed in platelet-
rich plasma (PRP) from healthy volunteers, and in plate-
let-poor plasma (PPP) combined with "theoretically" high
and low TF concentrations to determine the minimal
amount of rFVIIa needed to produce maximal TG. In
vitro, we found that the amount of TG is greatly depen-
dent on TF and rFVIIa concentration when these are
used alone, but is independent of rFVIIa concentration
when combined with TF. These results could have impor-
tant clinical implications for using low doses of rFVIIa.
Materials and methods
Subjects
Twenty-nine healthy volunteers (18 women and 11 men)
with no history of thromboembolic or hemorrhagic dis-
eases, cardiac, renal, hepatic, or malignant diseases, were
r eq u i r ed  t o  be  d r u g  f r e e  f o r  1 0  d a y s  be f o r e  t h e  s t u d y .
Informed consent was obtained from all volunteers
before participating in the study. Only subjects with a
normal platelet count, prothrombin time, and activated
partial thromboplastin time that fulfilled the inclusion
criteria were used for the TG assay with rFVIIa. Twenty
two PPP samples from the same normal volunteers (13
w o m e n  a n d  9  m e n )  w e r e  u s e d  t o  t e s t  T F  o r  T F  p l u s
rFVIIa in TG assays. The protocol was approved by the
institutional review board.
Methods
The methodology was similar to that previously
described [6]. Fluorogenic thrombin substrate (Z-Gly-
Gly-Arg-AMC; Bachem, Switzerland) was dissolved in
dimethylsulfoxide (DMSO) at a concentration of 100
mM. A stock solution was prepared containing 100 mM
fluorogenic substrate, 1 M CaCl2 and Fluo Buffer (20
mmol/l HEPES, pH 7.35, containing 60 mg/ml bovine
serum albumin (Sigma, St. Louis, MO, USA). For the TG
assays, a working solution containing 2.5 mM fluorogenic
substrate, 100 mM CaCl2, and 2.5% (v/v) DMSO were
used. rFVIIa was Novo Seven, from NovoNordik,
Bagsvćrd, Denmark. Tissue factor containing 5 pM TF
and 4 μM phospholipids was supplied by Synapse BV
(Maastricht, The Netherlands; PPReagent cat. no. TF
30.00).
Thrombin generation study
Venous blood was withdrawn from the antecubital vein
without stasis and mixed with 0.11 M sodium citrate
(1:10 v/v). The PRP was obtained by centrifugation at 150
×  g  for 10 min at room temperature, and PPP was
obtained by centrifuging the PRP at 900 × g for 15 min.
The PRP was adjusted to a platelet count of 290,000-
310,000/μl with autologous PPP. If contamination of PRP
w i t h  e ry t h r o cyt e s  o r  l e u k o cy t e s  w a s  o b s e rv e d  b y  l i g h t
microscopy, a second centrifugation at 900 × g for 5 min
was carried out to minimize the number of these cells.
Plastic syringes, tubes, and pipettes were used for all
tests. To prevent the inclusion of normal volunteers who
may have taken any drug capable of affecting platelet
function, platelet aggregation in the PRP was measured
photometrically in a double-channel Lumi-Aggregometer
(Chrono-log Corp., Havertown, PA, USA). Light trans-
mittance was set at 10% for PRP and 90% for PPP. The
aggregating agent (1-10 μl) was added to the PRP in the
aggregometer at 37°C with constant stirring (1000 rpm);
AA 0.75 mM and ADP 2 μM were used as platelet-aggre-
gating agents. If samples from normal volunteers showed
abnormal platelet aggregation in response to AA or ADP,
they were discarded and the results were excluded from
the study. Platelet activation is a very sensitive process
and activation during blood withdrawal or PRP prepara-
tion could affect the final results. To prevent this bias, if
the lag time (LT) in PRP samples was less than 1 standard
deviation below the average, it was considered activated
and was discarded.
TG was measured using the calibrated automated
thrombography (CAT) method [7] and assayed using an
intrinsic coagulation system in which platelets in the PRP
were activated with rFVIIa. TG was also measured in PPP
by adding TF or TF plus rFVIIa. Samples were assayed in
round-bottom polypropylene microtiter plates (Greiner
Labortechnik, Germany) using a microtiter plate fluorim-
eter (Fluoroskan Ascent reader, Thermo Labsystems Hel-
sinki, Finland). Tests were performed a mean of 62 ± 15
min after blood collection. In PRP, the assay system con-
sisted of 80 μl of PRP and 20 μl of rFVIIa solution to
obtain final concentrations of 5.0 μg/mL, 2.6 μg/mL, 0.5
μg/mL, 0.25 μg/mL, and 0.125 μg/mL for rFVIIa. In PPP,
the assay system was 80 μL of PPP and final TF concen-
trations of 5.0 pM, 2.5 pM, 1.25 pM, or 0.5 pM alone, or
combined with 5.0 μg/mL, 2.6 μg/mL, or 0.5 μg/mL
rFVIIa. Registration was initiated at the same time as the
fluorogenic working solution was automatically added.
Fluorescence was measured at 15-s intervals over a
period of 50 min. Each sample was assayed simultane-
ously in four replicates.
The rFVIIa concentrations of 5.0 μg/mL, 2.6 μg/mL,
and 0.5 μg/mL used in both systems are comparable with
the predicted concentrations of rFVIIa achieved in
plasma by intravenous administration of approximately
200 μg/kg, 104 μg/kg, and 20 μg/kg in vivo, respectively.
The lower rFVIIa concentrations of 0.25 μg/mL and 0.125
μg/mL were used to establish the plateau of the rFVIIa
activated assay.Altman et al. Thrombosis Journal 2010, 8:8
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Definitions
The LT is the time (in minutes) from the start of the assay
to the initial generation of thrombin (the moment that 10
nM thrombin is formed).
Time to peak TG (TTP) is the time (in minutes)
required to reach maximum TG.
Peak TG (PTG) is the maximum thrombin concentra-
tion (nM).
Endogenous thrombin potential (ETP) is the area under
the curve (AUC) (nM thrombin). ETP was calculated and
corrected for α2 macroglobulin-thrombin complex activ-
ity using Thrombinoscope (Maastricht, Netherlands)
software. To ensure comparability of results, the AUC
was calculated assuming that the start of the tail occurred
at 35 min (AUCoT35 min).
Statistical analysis
Quantitative variables are expressed as the mean ± stan-
dard deviation. The nature of the quantitative variable
distribution was explored through the Shapiro-Wilk's
test. Differences among groups of quantitative data were
tested using one-way analysis of variance (ANOVA).
Scheffé post hoc test was applied for multiple between-
group comparisons. In case of non normally distributed
data, Kruskal-Wallis tests (KW) were also performed
(Student-Newman-Keuls post hoc). A log transformation
of the quantitative data was also carried out, and tested
through one way ANOVA (LogANOVA). Significance
from these tests (KW and LogANOVA) are computed
only when relevant differences with regards to the one
way ANOVA obtained from the raw data were found. A p
values below 0.05 was considered significant. The soft-
ware, CSS/Statistica (Software: Statistica v9, 2010, Tulsa,
OK, US.) was used for the analyses.
Results
Effects of rFVIIa on TG parameters in PRP
When normal PRP was activated with different concen-
trations of rFVIIa, results obtained with all concentra-
tions used were statistically different from saline-treated
P R P .  W h e n  r FV I I a  5 . 0  μ g / m L  w a s  c o m p a r e d  w i t h  t h e
other rFVIIa concentrations (2.6 μg/mL, 0.5 μg/mL, 0.25
μg/mL, and 0.125 μg/mL) the LTs were progressively lon-
ger (Fig. 1) indicating a dose-dependent rFVIIa activity,
although the difference between the lowest concentra-
tions (0.5 μg/mL, 0.25 μg/mL, and 0.125 μg/mL) was not
statistically significant. An unexpected tendency (some
statistically significant) to increase PTG at the lower
rFVIIa concentrations was observed. PTG was statisti-
cally lower (Fig 2) when rFVIIa 5.0 μg/mL was compared
with 0.5 μg/mL, but the other concentrations (0.25 μg/mL
and 0.125 μg/mL) were not sensitive to rFVIIa dose varia-
tions. Based on these results, we decided to use only the
h i g h e r  c o n c e n t r a t i o n s  o f  r FV I I a  i n  s u b s e q u e n t  e x p e r i -
ments.
Effects of TF and rFVIIa on TG parameters
The PPP was used in this set of experiments. The amount
of TF released after injury to a blood vessel wall is
unknown. We arbitrarily used rTF concentrations of 5.0
pM, 2.5 pM, 1.25 pM, and 0.5 pM. Increased concentra-
tions of TF dose-dependently shortened the LT and
increased PTG and AUCoT35 min levels (Table 1); these
changes were statistically significant.
The addition of rFVIIa increased the effect of TF on the
LT and AUCoT35 min, but not the PTG. Moreover, differ-
ences between different concentrations of rFVIIa were
not observed (Table 1).
Discussion
The relationship between rFVIIa concentration and TG
when rFVIIa is used in combination with TF is unknown.
In this study, we wanted to establish the correlation
between different amounts of rFVIIa in combination with
TF on TG when added to normal PRP or PPP in vitro.
The rFVIIa concentrations used in these in vitro exper-
iments are comparable with the predicted concentrations
o f  r FVII a  a c h i ev ed  i n  p las m a  b y  t h e  a d m i n is t r a t i o n  o f
high (approximately 200 μg/kg), moderate (104 μg/kg), or
low (20 μg/kg) doses. Results obtained with rFVIIa con-
centrations of 5 μg/mL, 2.6 μg/mL, 0.5 μg/mL, 0.125 μg/
mL, and 0.25 μg/mL were significantly different com-
pared with saline (p < 0.001) for all TG parameters (Fig. 1,
2). Comparing the effect of different doses of rFVIIa, the
LT were statistically longer with decreasing doses when
rFVIIa 5.0 μg/ml was compared with the other concen-
trations. Nevertheless, there was no difference among the
l o w e s t  r FV I I a  c o n c e n t r a t i o n s  ( 0 . 5  μ g / m L ,  0 . 2 5  μ g / m L ,
and 0.125 μg/mL) (Fig 1). Unexpectedly, the PTG was sta-
tistically lower when rFVIIa 5.0 μg/ml was compared
with 0.5 μg/ml. The other concentrations were similar
and independent of the rFVIIa concentration (Figure 2).
Thus, only the highest concentrations of rFVIIa (5.0 μg/
mL, 2.5 μg/mL, and 0.5 μg/mL) were combined with TF
to evaluate the effects on TG parameters.
After injury, there is a combined effect of factor VII and
TF in forming the hemostatic plug. In the vessel wall, TF
is constitutively expressed in subendothelial cells, leading
to rapid initiation of coagulation when the vessel is dam-
aged. The amount of TF exposed after injury to the blood
vessel wall is unknown, as is the contribution of soluble
TF. We arbitrarily used TF concentrations of 5.0 pM, 2.5
pM, 1.25 pM, and 0.5 pM. All of these concentrations
produced a statistically significant, TF dose-dependent
decrease in the LT and an increase in the PTG and AUC
(AUCoT35 min) (p < 0.001 for all comparisons). The addi-Altman et al. Thrombosis Journal 2010, 8:8
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tion of rFVIIa increased the effect of TF in shorting the
LT and increasing the AUCoT35 min with no effect on PTG
(Table 1). These effects are independent of rFVIIa con-
centration. Indeed, using rFVIIa concentrations of 5 μg/
ml, 2.6 μg/ml, or 0.5 μg/ml with fixed concentrations of
TF, no differences in TG parameters were observed.
These experiments indicate that rFVIIa, even at low
concentrations, in the presence of TF can induce TG in a
very short time, an effect that is not dependent on rFVIIa
concentration.
In hemophilic patients with inhibitors, rFVIIa is effec-
tive in controlling mild to moderate bleeding. Safety data
indicate that thromboembolic events are low in these
patients. However, when used for off-label indications,
rFVIIa-related thrombotic events seem to occur more
frequently [8].
The mechanism of action of rFVIIa explains its efficacy
in congenital and acquired hemophilia A and B [9-11],
and in a range of clinical situations characterized by
i m p a i r e d  T G ,  s u c h  a s  l i v e r  d i s e a s e ,  p l a t e l e t  d i s o r d e r s ,
antivitamin K therapy, antiplatelet therapy [6], and others
(excessive bleeding, surgery and trauma, acute intracere-
bral hemorrhage, cardiovascular surgery) [3,12-14].
The prohemostatic properties of rFVIIa may theoreti-
cally have a downside in the form of potential arterial or
venous thrombosis associated with its use in adults [15-
17] and children [18,19] often resulting in mortality and
serious morbidity (deep venous thrombosis, myocardial
infarction) [20,21].
Added in pharmacological doses, exogenous rFVIIa
together with platelet agonists enhances the rate of TG
[22] by activating platelet surfaces, increasing the expo-
sure of membrane phospholipids at the site of injury, and
initiating local clotting mechanisms [23]. Thrombotic
events could be related to local concentrations of throm-
bin.
Increasing rFVIIa infusions increases the possibility of
thrombosis in medical conditions not related to hemo-
philia with inhibitors [13,14]. A low dose of 1.2 mg of
rFVIIa administrated to a study population with trau-
matic brain injury, warfarin use, and cirrhosis led to a
reduction in the mean prothrombin time from 17.0 ± 3.2
Figure 1 Effect on the lag time and time to peak thrombin generation with different concentrations of recombinant factor VIIa (5 μg/μL 
down to 0.125 μg/μL). Results are expressed as the mean values of samples obtained from 29 volunteers. Arrows indicate a statistical difference be-
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s to 10.6 ± 1.4 s (p < 0.0001) [5] indicating an important
increase in thrombin formation easily detected with this
basic clotting test.
Some clinical conditions that are mediated by TF expo-
sure in the circulation may theoretically carry a risk of
adverse thrombotic reactions upon administration of
rFVIIa. An example of such a condition is patients with
semi-ruptured atherosclerotic plaques that are known to
contain abundant TF. In this situation, rFVIIa may hypo-
thetically precipitate an acute thrombotic event, such as a
myocardial infarction [20,21]. Another condition that is
associated with systemic TF release into the circulation is
disseminated intravascular coagulation: TF, expressed on
the surface of activated mononuclear cells and endothe-
lial cells, activates factor VII [24]. Moreover, in patients
with antecedents of myocardial infarction, elevated levels
of circulating microparticles originating from platelets,
and endothelial cells can be associated with thrombotic
disorders [25]. Administration of rFVIIa could theoreti-
cally lead to a more severe coagulopathy and aggravate
systemic microvascular thrombosis when combined with
TF released from monocytes [24,26].
In hemophilia with inhibitors, the dose of rFVIIa used
can be as high as 270 μg/kg [27]. Smaller doses showed
satisfactory results in some off-label conditions, such as
cardiac patients with intractable bleeding [4,28] and
trauma patients with coagulopathy [5]. For instance, 1.2
mg effectively treated mild to moderate coagulopathy fol-
lowing injury, 1.2 mg and less than 90 μg/kg were effec-
tive for severe bleeding in cardiac surgery with few or no
thrombotic events, and 20 μg/kg or 40 μg/kg resulted in a
50% reduction in blood loss in patients with a pre-exist-
ing normal coagulation system undergoing abdominal
prostatectomy[29]. In the paper by Diringer et al. [21]
there were 49 (27%) arterial events in the placebo group,
and in the rVIIa treated group, there were 47 (26%) arte-
rial events in the 20-microg/kg group, and 82 (46%) in the
80 microg/kg group (P = 0.04).
In conclusion, this data might be helpful in studying the
effect of low dose of rTFIIa in bleeding situations where
Figure 2 Effect on the amount of thrombin generation (peak thrombin generation or PTG) and area under the curve (AUCx10) of different 
concentrations of recombinant factor VIIa (rFVIIa) (5 μg/μL up to 0.125 μg/μL). Results are expressed as the mean values of samples obtained 
from 29 volunteers. Arrows indicate a statistical difference between values. When saline was compared with all rFVIIa concentrations, p < 0.001 (one-








































Altman et al. Thrombosis Journal 2010, 8:8
http://www.thrombosisjournal.com/content/8/1/8
Page 6 of 7
arterial or venous thrombosis can occur despite bleeding.
This seems to fit with some clinical obsevations regarding
the efficacy of low-dose rFVIIa in stopping bleeding in
off-label indications.
For off-label use, no particular dose of factor rVIIa is
recommended in the literature, and thromboembolic
events may be dose dependent [30]. Using the smallest
possible dose is warranted not only because of the
expense of factor rVIIa, but because of the potential
thromboembolic events [30].
In this context and because rFVIIa may increase the
risk of arterial thrombosis [31], we speculate that using
excess rFVIIa in off-label indications combined with TF
generated in disrupted or inflamed atheromas or other
clinical conditions can induce thrombotic events, since
the TF-FVIIa complex drives the intrinsic coagulation
pathway to form thrombin and fibrin [32].
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